Press Releases

  • 16 Jun 2016
    - Press Release

    EBE, the European Biopharmaceutical Trade Association, Unveils Its Leadership 2016-2018

    (16 June 2016 – Brussels, Belgium): The European Biopharmaceutical Enterprises, EBE, is pleased to announce its Board of Directors for the term 2016-2018, following the decisions taken at the EBE and EFPIA (European Federation of Pharmaceutical Industries and Associations) Annual Meetings on 14 to 16 June 2016.

    Read more | Download Document (222.68 kB)
  • 06 Jun 2016
    - Press Release

    EBE and EFPIA Applaud EMA Initiative to Improve Pathway for Advanced Therapy Medicinal Products (ATMPs)

    EBE and EFPIA both welcome sincerely the initiative taken by the European Medicines Agency to identify concrete solutions to foster the development of advanced therapy medicinal products, while simultaneously embarking on concerted efforts to expand patient access to them across Europe.

    Read more | Download Document (100.71 kB)
  • 01 Jun 2016
    - Press Release

    EBE Annual General Meeting 2016

    The EBE Annual Meeting will take place on 14 June 2016 in Brussels from 16h00 to 19h00, at the Radisson Blu Hotel, Rue Fossé-aux-Loups 47 (Room Royale), in close coordination with the EFPIA Statutory General Assembly at the same venue on 15 June.

    Following the Statutory part of the meeting (from 16-17h) we are proud to offer an opportunity for information and debate to all our members though our session dedicated to IMI – opportunities and challenges for developing Advanced Therapies (from 17h00 to 19h00)

    A keynote speech by Pierre Meulien, Executive Director IMI, followed by a moderated panel discussion on the opportunities for EBE members.

    Read more | Download Document (41.92 kB)
  • 22 Feb 2016
    - Press Release

    EuropaBio and EBE host a multi-stakeholder debate on the labelling of biosimilar medicines

    On 2 February 2016, EuropaBio, the European Association for Bio Industries, and EBE, the European Biopharmaceutical Enterprises, jointly facilitated a multi-stakeholder workshop in Brussels on the labelling of biosimilar medicinal products. 40 people participated in the meeting, including representatives of EU and national associations of patients, physicians and pharmacists. Three representatives from the European Medicines Agency (EMA) attended the meeting as observers. 

    Update 3 May 2016: Meeting summary available for download


    Read more | Download Document (531.82 kB)